摘要
目的:分析养血清脑颗粒联合奥拉西坦治疗脑梗死急性期血管认知功能障碍的临床疗效。方法:对过去一年(2014年10月—2015年10月)在我院神经内科接受保守治疗的150例脑梗死急性期血管认知功能障碍患者进行联合治疗和单一药物治疗的临床疗效对比研究,依照对每位患者所采取的治疗方案不同将所有患者均分至A、B两组。其中,A组患者采用养血清脑颗粒进行治疗,B组则在A组基础上联合奥拉西坦进行治疗。对比分析A、B两组不同治疗方案对脑梗死患者认知障碍的临床效果。结果:A、B两组脑梗死急性期血管认知功能障碍患者的总有效率分别为77.33%、93.33%,二者临床疗效差异显著,P<0.05,有统计学意义。在MMSE评分上,治疗后A组患者评分也明显低于B组;而经治疗后的ADAS-Cog量表评分则A组患者明显高于B组,即B组患者认知功能改善显著,二者差异显著,P<0.05,有统计学意义。结论:养血清脑颗粒联合奥拉西坦治疗脑梗死患者认知障碍不仅临床疗效显著,而且患者认知功能评分高,值得重视推广。
Objective：To analysis clinical curative effectof Yangxue Qingnao Granule combined with oxiracetam in treatment of cerebral infarction in acute stage vascular cognitive impairment. Methods：In the past year（2014.10—2015.10）department of neurology in our hospital received conservative treatment of 150 cases with acute cerebral infarction in vascular cognitive impairment,comparedthe therapeutic effects of combination therapy and single drug therapy,according to different treatments, all patients were divided into group A and group B. The patients in group A were treated with Yangxue Qingnao Granule,group B combined with oxiracetam treatment on the basis of group A. To compare the clinical effects of two groups. Results：The total effective rate of vascular cognitive impairment in patients with acute cerebral infarction was 77.33% and 93.33% in group A and B,respectively,and the difference was significant between the two groups,P〈0.05. In the MMSE score,after treatment,score of group A was significantly lower than that of group B;and the amount of ADAS-Cog scoreafter the treatment of group A was significantly higher than that of group B,the cognitive function of patients in group B was significantly improved,P〈0.05,with statistical significance. Conclusion：Yangxue QingnaoGranule combined with oxiracetam treatment clinical curative effect was distinct,and cognitive function in patients with high scores,worthy of paying attention to promote.
出处
《辽宁中医药大学学报》
CAS
2016年第12期211-213,共3页
Journal of Liaoning University of Traditional Chinese Medicine
关键词
养血清颗粒
脑梗死
认知障碍
奥拉西坦
Yangxue Qingnao Granule
cerebral infarction
cognitive impairment
oxiracetam
